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ABSTRACT  
The in situ drug delivery system and colloidal formulation like micro emulsion has potential to use in ocular delivery. Micro emulsion 
provides better permeation of drug through the membrane and provides improved bioavailability. The in situ drug delivery system 
decreases pre-corneal drainage, increase the contact time of formulation with eye and prolong the release in ocular tissues. Again, in situ 
gelling system has advantage of delivering accurate and reproducible quantities each time, against any already gelled formulations. To 
combine the benefits of these two dosage forms, micro emulsion based in situ gelling system can be developed as a novel vehicle for 
ophthalmic drug delivery. Endophthalmitis is an infection of intraocular fluids like vitreous humor and ocular tissues. To combat the 
disease, the formulation which provides sufficient concentration in posterior segment eye diseases (PSED) is required. 
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Introduction 
Common Ocular Disorders 
The anterior segment of eye consists of the front one-third of 
the eye that includes; pupil, cornea, iris, ciliary body, aqueous 
humor, and lens and the posterior segment of the eye 
consists of the back two-thirds of the eye that includes 
vitreous humor, retina, choroid, macula, and optic nerve. 
Accordingly, the common ocular diseases can be classified as 
anterior segment disorders and posterior segment disorder 
1.  
Anterior segment disorders 
 Conjunctivitis & Scleral Diseases 
 Corneal Disorder 
 Eyelid & Tearing disorder 
 Glaucoma 
 Cataract etc. 
Posterior segment disorders  
 Optic Nerve disorders 
 Choroidal disorders 
 Uvetitis 
Introduction to Endopthalmitis 
Endopthalmitis is an infection inside the eye. It is very 
uncommon disease. It is caused by organisms that may enter 
the eye through a surgical incision [1] or an injury to the 
eyeball or, very rarely, has travelled through bloodstream 
into the eye. Possible causes of infection in the bloodstream 
are intravenous drug use, an abscess (a collection of pus), 
and skin ulcers, infections such as pneumonia or sepsis, or 
surgery anywhere in the body. Bacteria are mainly 
responsible for the infection but it may also occur due to 
fungi or protozoa. Viruses may causes an eye infection, 
but this type of infection does not include under the 
classification of Endophthalmitis 2. 
Common types of Endophthalmitis 
Two broad categories of endophthalmitis are Infectious 
Endophthalmitis and Non-infectious Endophthalmitis 3. 
The infectious endophthalmitis are further distinguished 
into endogenous and exogenous infections. Exogenous 
infection results from introduction of organisms into the 
eye through a surgical or traumatic penetrating wound. 
Endogenous (or metastatic) infection is caused by 
organisms that enter the eye via the bloodstream. Both 
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categories of infection are extremely serious, threatening 
blindness and even loss of the globe. 
Causative organisms of Endopthalmitis 
The term endophthalmitis is referred as bacterial, fungal 
or protozoal infection which involves intraocular tissues 
(retina, uveal tract, or lens) or ocular fluids (vitreous or 
aqueous). A bacterium isolated from post–operative 
Endophthalmitis contains about 94.2 % of gram positive 
bacteria (70% due to Staphylococcus epidermidis). Other 
commonly found pathogens are Staphylococcus aureus, 
Streptococcus pneumoniae, Streptococcus pyogenes, 
propionibacterium acnes, Haemophilus influenza, E coli, 
Bacillus cereus, Neisseria gonorrhoea, and Proteus 
mirabilis 4. 
Signs and Symptoms 
Symptoms of endophthalmitis include pain, redness, high 
sensitivity to bright light, and partial or almost complete 
loss of vision. Sometimes these may be very severe. Other 
most common signs of endophthalmitis are decreased 
vision, mild to moderate anterior chamber reaction, 
hypopyon (pus in the eye), vitritis, variable pain, 
conjunctival hyperaemia, chemosis, lid oedema, corneal 
oedema, poor fundal glow. Figure shows 78-year-old 
man’s eye with the symptoms of endophthalmitis 5. 
 
 
Figure 1: Staphylococcus epidermidis chronic endophthalmitis in a 78- year-old man 
A: Frontal view. B: Tangential view. 
(Courtesy: Survey of Ophthalmology, Michael S. Kresloff et al.) 
 
Detection and Diagnosis 
The diagnosis of endopthalmities is symptomatic. It 
involves an eye and culture examination. Sometimes 
antibody or DNA testing also required. For diagnosis, 
cultures are taken from the aqueous humor and the 
vitreous humor and plated on sheep blood agar, chocolate 
agar, thioglycolate broth, and Sabrouraud's dextrose 
media and smears are treated with Giemsa and Gram 
staining to found out the responsible organism and also to 
found out the drugs which is most active against them 6. 
Drugs used in Endophthalmitis 
For an ocular antibiotic selection, one should evaluate 
four main characteristics of antibiotic. First, the drug must 
be able to effectively penetrate into the intraocular 
tissues. Second, the drug must be of adequate potency, 
which, in the case of antibiotics, is measured by the mean 
inhibitory concentration (MIC). Third, there must be 
minimal bacterial resistance to the drug. Finally, the drug 
should be able to rapidly eradicate bacteria, before 
infection is able to set in. Generally, the broad spectrum 
antibiotic is required for the severe vision-threatening 
infections such as Endophthalmitis. The fourth-generation 
fluoroquinolones such as Ciprofloxacin (Vigamox) and 
Gatifloxacin (Zymar), can provide better coverage for 
gram-positive and resistant organisms than the third-
generation fluoroquinolone such as levofloxacin (Quixin, 
Iquix), and the second-generation fluoroquinolones such 
as Ciprofloxacin (Ciloxan) and Ofloxacin (Ocuflox). 
Ciprofloxacin and Gatifloxacin provides improved 
spectrum of activity as well as increased penetration into 
ocular tissues, and delayed propensity to the development 
of bacterial antibiotic resistance. Considering 
photosensitivity of drug, Ciprofloxacin and Gatifloxacin 
are not photosensitive like other halogenated 
fluoroquinolones (i.e. Clinafloxacin, Sitafloxacin, and 
Lomefloxacin). Ciprofloxacin and Gatifloxacin possess 
methoxy group at the C8 position; instead of fluorine 
which is associated with photosensitivity. For these reasons 
Ciprofloxacin or Gatifloxacin can be best option for the 
treatment of endophthalmitis 7. 
Treatment options8 
Anti microbial therapy 
 Intra-vitreal 
 Topical 
 Peribulbar or Intra cameral 
 Systemic 
Anti-inflammatory therapy (NSAIDS & 
corticosteroids) 
 Intra-vitreal 
 Topical 
 Systemic 
Supportive therapy 
 Anti glaucoma medication 
 Vitamins 
Therapeutic challenges 
The factors to be considering during treatment of 
endopthalmities are delicate nature of the interior of the 
eye and the anatomic barriers. The key anatomic barriers 
that prevent adequate treatment of endophthalmitis are 
the inner and outer blood–retinal barrier and the blood–
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aqueous humor barrier, collectively called the blood–
ocular barrier. The blood–ocular barrier consists of tight 
junctions between the endothelial cells and basement 
membrane of retinal capillaries and retinal pericytes. The 
role of barrier is to protect the interior of the eye from 
assault by cells, macromolecules, and drugs & prevents 
the entrance and subsequent activity of most systemic 
antimicrobial and anti- inflammatory drugs. Direct 
injection of drugs into the vitreous humor can bypass the 
intraocular barriers. Photoreceptors and other cells of the 
retina are extremely sensitive to insult, and high doses of 
antimicrobial agents required to eradicate the bacteria 
from eye may induce toxic effects on the retina and it may 
potentially disrupting the biochemical pathways 
necessary for vision. For the treatment of some 
vitreoretinal diseases, systemic administration of drugs 
has been used. But the literature said that after systemic 
administration, very small amount of drugs could reach 
the eye. Therefore to obtain a therapeutic level of drug 
concentration in the eye, a large amount of systemic dose 
is required. 
Ocular Drug Delivery 
Anatomical and Physiological considerations in 
topical ocular delivery 
It is the tear film which provides corneal transparency 
and good visual function that require for uniform eye 
surface. The tear film covers and lubricates the cornea 
and the external globe. It is the first structure encountered 
by topically applied drugs and it shows the trilaminar 
structure of the tear film. Mucous layer is attached to the 
glycocalix of the corneal/conjunctival surface and it 
consists mainly of glycoproteins. It is responsible for the 
wetting of corneal and conjunctival epithelium and also 
for the stability of tear film. The middle aqueous layer 
composed of about 98% of the tear film. It is also 
composed of water, electrolytes, and various proteins such 
as lipocalin, lysozyme, and lactoferrin. The outermost lipid 
layer consists of sterol esters, triacylglycerols, and 
phospholipids. The main role of this layer is to prevent the 
evaporation of the tear fluid and is spread over the 
aqueous layer during blinking 9. 
Nasolacrimal drainage system 
The lacrimal gland is responsible for most of the tear fluid 
secretion. Secreted fluid is spread over the surface of the 
cornea during blinking and ends up in the puncta when 
the upper eye lid approaches the lower lid. The blinking 
process creates a suction mechanism which results in 
tears flowing through the lacrimal canaliculi into the 
lacrimal sac. Fluid from the lacrimal sac then drains into 
the 12 mm long nasolacrimal duct, which empties into the 
inferior nasal passage. This passage is a highly vascular 
area and is responsible for most of the systemic drug 
absorption and subsequent systemic side effects of 
topically administered drug 10. 
Transport barriers in the eye 
Topical administration is the most common route for 
ocular drug delivery. Consequently, the cornea, 
conjunctiva, and sclera form the most essential barriers 
for drug penetration into the intraocular tissues. 
Cornea: 
The cornea is composed of five layers: It is considered to 
be the main pathway for ocular penetration of topically 
applied drugs. However, due to its unique structure, with 
the hydrophilic stroma sandwiched between the highly 
lipophilic epithelium and the less lipophilic endothelium, 
the penetration of compounds through the cornea 
depends on their n-octanol - water partition coefficient. 
Only drugs with a partition coefficient between 10- 100 
that show both lipid and water-soluble properties can 
readily pass through cornea 11. 
Conjunctiva: 
The conjunctiva is a thin and vascular mucous membrane 
consisting of two to three layers of epithelial cells 
overlying a loose, highly vascular connective tissue. The 
tight junctions present on the apical surface of the 
epithelium act as the main barrier for drug penetration 
(molecules > 20,000 Da) across the tissue, although not as 
tight as the corneal epithelium, which is impermeable to 
molecules larger than 5000 Da. The conjunctiva covers the 
anterior surface of the globe (bulbar conjunctiva), with the 
exception of cornea, and is folded at the fornix (fornix 
conjunctiva) to form the palpebral conjunctiva, which 
lines the inner surface of the eyelids. The bulbar 
conjunctiva represents the first barrier for permeation of 
topically applied drugs via the non-corneal route. 
Sclera: 
The sclera is the outermost firm coat of the eye that 
serves as a protective barrier for the sensitive inner parts. 
It is composed of the same type of collagen fibers as the 
corneal stroma. However, the fibers are arranged in an 
irregular network rather than a lattice pattern, which 
makes the tissue appear opaque compared to the 
transparent cornea. The white sclera constitutes the 
posterior 5/6th of the globe, whereas the transparent 
cornea comprises the anterior 1/6th of the globe 12. 
Protective blood – ocular barriers: 
The blood-ocular barriers can be divided into blood-
aqueous barrier and blood-retinal barrier. The blood-
aqueous barrier is located in anterior part of the eye and is 
formed by endothelial cells of the blood vessels in iris and 
non-pigmented cell layer of the ciliary epithelium. It 
regulates the solute exchange between the blood and the 
intraocular fluid, preventing unspecific passage of solutes 
that could influence the transparency of the ocular tissues. 
The outward movement into the systemic blood 
circulation is less restricted, allowing especially small and 
lipophilic drug molecules to enter the uveal blood 
circulation. These molecules are consequently removed 
more rapidly from the anterior chamber than larger, 
hydrophilic molecules, which are eliminated by the 
aqueous humor turnover only. The blood – retinal barrier 
can be found in the posterior part of the eye. It prevents 
toxic molecules, plasma components, and water from 
entering the retina. It also forms a barrier for passage of 
systemically administered drugs into the vitreous, 
typically resulting in only 1-2% of the drug’s plasma 
concentration in the intraocular tissues 13. 
Ocular drug delivery approaches 
They offer some advantages such as their ease of 
administration by the patient, ease of preparation, and the 
low production costs. However, there are also significant 
disadvantages associated with the use of conventional 
solutions in particular, including the very short contact 
time with the ocular surface and the fast nasolacrimal 
drainage, both leading to a poor bioavailability of the 
drug. 
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Polymeric delivery systems 
Polymeric systems used for ocular drug delivery can be 
divided into three groups: viscosity enhancing polymers, 
which simply increase the formulation viscosity, resulting 
in decreased lacrimal drainage and enhanced 
bioavailability; mucoadhesive polymers, which interact 
with the ocular mucin, therefore increasing the contact 
time with the ocular tissues; and in situ gelling polymers, 
which undergo sol-to-gel phase transition upon exposure 
to the physiological conditions present in the eye 14. 
Viscosity -enhancing polymers: 
In order to reduce the lacrimal clearance (drainage) of 
ophthalmic solutions, various polymers have been added 
to increase the viscosity of conventional eye drops, 
prolong pre-corneal contact time, and subsequently 
improve ocular bioavailability of the drug. Among the 
range of hydrophilic polymers investigated in the area of 
ocular drug delivery are polyvinyl alcohol (PVA) and 
polyvinyl pyrrolidone (PVP), cellulose derivates such as 
methylcellulose (MC), polysaccharides, poly methylvinyl 
ether maleic anhydride and polyacrylic acids (carbopols). 
Typically, these polymers are high molecular weight 
molecules (5,000 - 100,000 Da), that cannot cross biological 
membranes 15. 
Mucoadhesive polymers: 
Bioadhesion refers to the attachment of a drug molecule or 
a delivery system to a specific biological tissue by means 
of interfacial forces. If the surface of the tissue is covered 
by a mucin film, as is the case for the external globe, it is 
more commonly referred to as mucoadhesion. Cationic 
polymers (like chitosan), which are able to interact with 
the negative sialic acid residues of the mucin, would 
probably show better mucoadhesive properties than 
anionic or neutral polymers. The most commonly used 
bioadhesives are macromolecular hydrocolloids with 
numerous hydrophilic functional groups capable of 
forming hydrogen bonds (such as carboxyl, hydroxyl, 
amide, and sulfate groups). Hyaluronic acid is also most 
promising mucoadhesive polymer in ocular drug delivery 
16.
 
 
Figure 2: Mucoadhesive polymers in the design of nano-drug delivery systems 
 
Role of Micro emulsion based in situ gelling 
system 
The use of preformed gels still has drawbacks that can 
limit their interest for ophthalmic drug delivery. They do 
not allow accurate and reproducible administration of 
drugs and after administration; they often produce 
blurred vision, crusting of eyelids, and lacrimation. In situ 
gelling approach amalgamates the advantages of both 
solutions and gels, such as accuracy and facility of 
administration of the former and prolonged residence time 
of the latter. Thus in situ gels can be instilled as eye drops 
and undergo an immediate gelation when in contact with 
the eye. In situ forming gels are liquid upon instillation and 
undergo phase transition in the ocular cul-de-sac to form 
viscoelastic gel and this provides a response to 
environmental changes 17. 
Colloidal Drug Delivery System 
Colloidal carriers are small particulate systems ranging in 
size from 100 to 400 nm. As they are usually suspended in 
an aqueous solution, they can easily be administered as 
eye drops, thus avoiding the potential discomfort 
resulting from bigger particles present in ocular 
suspensions or from viscous/sticky preparations 18. Most 
efforts in ophthalmic drug delivery have been made with 
the aim of increasing the corneal penetration of the 
drug 19. 
Colloidal particles are preferably taken up by the corneal 
epithelium via endocytosis. Cornea acts as a drug 
reservoir, slowly releasing the active compound present 
in the colloidal delivery system to the surrounding ocular 
tissues. 
Nanoparticles: 
Nanoparticles are defined as submicrometer sized 
polymeric colloidal particles ranging from 10 to 1000 nm 
in which the drug can be dissolved, entrapped, 
encapsulated, or adsorbed. Depending on the preparation 
process, nanospheres or nanocapsules can be obtained. 
Nanospheres have a matrix like structure where the drug 
can either be adsorbed at the surface of the particle or be 
dispersed/dissolved in the matrix. Nanocapsules, on the 
other hand, consist of a polymer shell and a core, where 
the drug can either be dissolved in the inner core or be 
adsorbed onto the surface 20. 
The most commonly used biodegradable polymers in the 
preparation of nanoparticulate systems for ocular drug 
delivery are poly-alkylcyanoacrylates, poly- -caprolactone, 
and polylactic-co-glycolic acid copolymers. The major 
limiting issues for the development of nanoparticles 
include the control of particle size and drug release rate as 
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well as the formulation stability. There is only one 
microparticulate ocular delivery system in the market, 
Betoptic S 0.25%. It is obtained by binding of betaxolol to 
ion exchange resin particles and is found to be 
bioequivalent to the Betoptic 0.5% solution in lowering 
the intraocular pressure 21. 
 
Figure 3: Nanoparticles 
Liposomes: 
Liposomes are potentially valuable as ocular drug 
delivery systems due to their simplicity of preparation 
and versatility in physical characteristics. However, their 
use is limited by instability (due to hydrolysis of the 
phospholipids), limited drug loading capacity, technical 
difficulties in obtaining sterile preparations and blurred 
vision due to their size and opacity. In addition, liposomes 
are subject to the same rapid precorneal clearance as 
conventional ocular solutions, especially the ones with a 
negative or no surface charge. Positively charged 
liposomes, on the other hand, exhibit a prolonged 
precorneal retention due to electrostatic interactions with 
the negative sialic acid residues of the mucin layer. There 
have been several attempts to use liposomes in 
combination with other newer formulation approaches, 
such as incorporating them into mucoadhesive gels or 
coating them with mucoadhesive polymers 22. 
Niosomes: 
Niosomes are nonionic surfactant vesicles which exhibit 
the same bilayered structures as liposomes. In order to 
circumvent some of the limitations encountered with 
liposomes, such as their chemical instability, the cost and 
purity of the natural phospholipids, and oxidative 
degradation of the phospholipids, niosomes have been 
developed. Niosomes are biocompatible, biodegradable, 
and nonimmunogenic. They will be also shown to increase 
the ocular bioavailability of hydrophilic drugs 
significantly more than liposomes. This is due to the fact 
that the surfactants in the niosomes act as penetrations 
enhancers.
 
 
Figure 4: Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development 
 
Microemulsions: 
Microemulsions (MEs) are colloidal dispersions composed 
of an oil phase, an aqueous phase, and one or more 
surfactants. They are optically isotropic and 
thermodynamically stable and appear as transparent 
liquids as the droplet size of the dispersed phase is less 
than 150 nm. One of their main advantages is their ability 
to increase the solubilization of lipophilic and hydrophilic 
drugs accompanied by a decrease in systemic absorption 
(59). They can also prolong the release of drug over 
definite period (46). Moreover, MEs are transparent 
systems thus enable monitoring of phase separation 
and/or precipitation. In addition, MEs possess low 
surface tension and therefore exhibit good wetting and 
spreading properties. The presence of surfactants is 
advantageous due to an increase in cellular membrane 
permeability, which facilitates drug absorption and 
bioavailability (60). Surfactants most frequently utilized 
for the preparation of MEs are poloxamers, polysorbates, 
and polyethylene glycol derivatives (61). Caution needs to 
be taken in relation to the amount of surfactant 
incorporated, as high concentrations can lead to ocular 
toxicity 23. 
Introduction to Drug 24 
Ciprofloxacin is an antibiotic used to treat a number 
of bacterial infections. This includes bone and joint 
infections, intra abdominal infections, certain type 
of infectious diarrhea, respiratory tract infections, skin 
infections, typhoid fever, and urinary tract infections, among 
others. For some infections it is used in addition to other 
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antibiotics. It can be taken by mouth, as eye drops, as ear 
drops, or intravenously.  
Common side effects include nausea, vomiting, diarrhea and 
rash. Ciprofloxacin increases the risk of tendon rupture. In 
people with myasthenia gravis, there is worsening muscle 
weakness. Rates of side effects appear to be higher than 
some groups of antibiotics such as cephalosporins but lower 
than others such as clindamycin. Studies in other animals 
raise concerns regarding use in pregnancy. No problems will 
be identified, however, in the children of a small number of 
women who took the medication. It appears to be safe 
during breastfeeding. It is a second-generation 
fluoroquinolone with a broad spectrum of activity that 
usually results in the death of the bacteria.  
Ciprofloxacin is patented in 1980 and introduced in 1987. It 
is on the World Health Organization's List of Essential 
Medicines, the most effective and safe medicines needed in 
a health system. It is available as a generic medication and is 
not very expensive.  
 
Figure 5: Structure of Ciprofloxacin 
Medicinal uses 
Ciprofloxacin is used to treat a wide variety of infections, 
including infections of bones and joints, endocarditis, 
gastroenteritis, external respiratory tract infections, 
cellulitis, urinary tract infections, prostatitis, anthrax.  
Ciprofloxacin only treats bacterial infections; it does not 
treat viral infections such as the common cold. For certain 
use including acute sinusitis, lower respiratory tract 
infections and uncomplicated gonorrhea, ciprofloxacin is not 
considered a first-line agent. Ciprofloxacin occupies an 
important role in treatment guidelines issued by major 
medical societies for the treatment of serious infections, 
especially those likely to be caused by Gram-negative 
bacteria, including Pseudomonas aeruginosa. For example, 
ciprofloxacin in combination with metronidazole is one of 
several first-line antibiotic regimens recommended by 
the Infectious Diseases Society of America for the treatment 
of community-acquired abdominal infections in adults. It 
also features prominently in treatment guidelines for acute 
pyelonephritis, complicated or hospital-acquired urinary 
tract infection, acute or chronic prostatitis, certain types of 
endocarditis, certain skin infections, and prosthetic joint 
infections 25. 
In other cases, treatment guidelines are more restrictive, 
recommending in most cases that older, narrower-spectrum 
drugs be used as first-line therapy for less severe infections 
to minimize fluoroquinolone-resistance development.  
Mechanism of action  
Ciprofloxacin is a broad-spectrum antibiotic of 
the fluoroquinolone class. It is active against some Gram-
positive and many Gram-negative bacteria. It functions by 
inhibiting DNA gyrase, and a type II topoisomerase, 
topoisomerase IV, necessary to separate bacterial DNA, 
thereby inhibiting cell division. 
Pharmacokinetics 
Ciprofloxacin for systemic administration is available as 
immediate-release tablets, extended-release tablets, an oral 
suspension, and as a solution for intravenous 
administration. When administered over one hour as an 
intravenous infusion,[28] ciprofloxacin rapidly distributes 
into the tissues, with levels in some tissues exceeding those 
in the serum. Penetration into the central nervous system is 
relatively modest, with cerebrospinal fluid levels normally 
less than 10% of peak serum concentrations. The serum 
half-life of ciprofloxacin is about 4–6 hours, with 50-70% of 
an administered dose being excreted in the urine as 
unmetabolized drug. An additional 10% is excreted in urine 
as metabolites. Urinary excretion is virtually complete 24 
hours after administration. Dose adjustment is required in 
the elderly and in those with renal impairment. 
Ciprofloxacin is weakly bound to serum proteins (20-40%), 
but is an inhibitor of the drug-metabolizing enzyme 
cytochrome P450 1A2, which leads to the potential for 
clinically important drug interactions with drugs 
metabolized by that enzyme. Ciprofloxacin is about 70% 
orally available when administered orally, so a slightly 
higher dose is needed to achieve the same exposure when 
switching from IV to oral administration 26. 
Adverse effects 
Adverse effects can involve the tendons, muscles, joints, 
nerves, and the central nervous system.  
Rates of adverse effects appear to be higher than with some 
groups of antibiotics such as cephalosporins but lower than 
with others such as clindamycin. Compared to other 
antibiotics some studies find a higher rate of adverse 
effects while others find no difference.  
In clinical trials most of the adverse events will be described 
as mild or moderate in severity, abated soon after the drug is 
discontinued, and required no treatment. Some adverse 
effects may be permanent. Ciprofloxacin is stopped because 
of an adverse event in 1% of people treated with the 
medication by mouth. The most frequently reported drug-
related events, from trials of all formulations, all dosages, all 
drug-therapy durations, and for all indications, will be 
nausea (2.5%), diarrhea (1.6%), abnormal liver function 
tests (1.3%), vomiting (1%), and rash (1%). Other adverse 
events occurred at rates of <1% [26]. 
Drug Delivery for Posterior Segment Eye 
Disease 
In recent years, significant advances have been made in 
optimizing the delivery of drugs to target tissues within the 
eye and in maintaining effective drug doses within those 
tissues. Most pharmacologic management of ocular disease, 
however, continues to use the topical application of 
solutions to the surface of the eye as drops. Factors that can 
limit the usefulness of topical drug application include the 
significant barrier to solute flux provided by the corneal 
epithelium and the rapid and extensive precorneal loss that 
occurs as the result of drainage and tear fluid turnover. After 
the instillation of an eyedrop (maximum of 30 μl) into the 
inferior fornix of the conjunctiva, the drug mixes with the 
lacrimal fluid, and drug contact time becomes a function of 
lacrimation, tear drainage and turnover, and to some extent 
the composition of the precorneal tear film itself. It has been 
estimated that typically less than 5% of a topically applied 
drug permeates the cornea and reaches intraocular tissues. 
The major portion of the instilled dose is absorbed 
systemically by way of the conjunctiva, through the highly 
vascular conjunctival stroma and through the lid margin 
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vessels. Significant systemic absorption also occurs when the 
solution enters the nasolacrimal duct and is absorbed by the 
nasal and nasopharyngeal mucosa. Despite the relatively 
small proportion of a topically applied drug dose that 
ultimately reaches anterior segment ocular tissues, topical 
formulations remain effective, largely because of the very 
high concentrations of drugs that are administered 27.  
Recent advances in topical drug delivery have been made 
that improve ocular drug contact time and drug delivery, 
including the development of ointments, gels, liposome 
formulations, and various sustained and controlled-release 
substrates, such as the Ocusert, collagen shields, and 
hydrogel lenses. The development of newer topical delivery 
systems using polymeric gels, colloidal systems, and 
cyclodextrins will provide exciting new topical drug 
therapeutics.  The delivery of therapeutic doses of drugs to 
the tissues in the posterior segment of the eye, however, 
remains a significant challenge.  
Currently, the treatment of posterior segment disease is to a 
significant extent limited by the difficulty in delivering 
effective doses of drugs to target tissues in the posterior 
eye (Fig.1) . Four approaches may be used to deliver drugs to 
the posterior segment–topical, systemic, intraocular, and 
periocular (including subconjunctival, sub-Tenon’s, and 
retrobulbar). Topically applied drugs may enter the eye by 
crossing the conjunctiva and then diffusing through the 
sclera, 3 4 but for reasons previously cited, this approach 
typically does not yield therapeutic drug levels in the 
posterior vitreous, retina, or choroid, and although systemic 
administration can deliver drugs to the posterior eye, the 
large systemic doses necessary are often associated with 
significant side effects. An intravitreal injection provides the 
most direct approach to delivering drugs to the tissues of the 
posterior segment, and therapeutic tissue drug levels can be 
achieved. Intravitreal injections, however, have the inherent 
potential side effects of retinal detachment, hemorrhage, 
endophthalmitis, and cataract. Repeat injections are 
frequently required, and they are not always well tolerated 
by the patient. Further, drugs injected directly into the 
vitreous are rapidly eliminated. Intravitreal sustained-
release devices have been used to avoid repeated injections. 
The best known of these devices is the Vitrasert ganciclovir 
implant, used in the treatment of cytomegalovirus 
retinitis. 5 These and other intravitreal sustained release 
systems, including other implant devices, microspheres, and 
liposomes, are exciting new modalities of drug delivery that 
offer effective treatment of visually devastating diseases. 
The devices, however, do require intraocular surgery, must 
be replaced periodically, and have potential side effects 
similar to those associated with intravitreal injection 28.
 
 
Figure 6: Delivery alternatives for Nanoparticles 
 
Periocular drug delivery using subconjunctival or 
retrobulbal injections or placement of sustained-release 
devices provides another route for delivering drugs to the 
posterior tissues of the eye. This approach to drug delivery 
is safer and less invasive than intravitreal injection and also 
offers the exciting potential for localized, sustained-release 
drug delivery. Drug delivery by this vector ideally would be 
transscleral and thus could take advantage of the large 
surface area of the sclera. The average 17-cm2 surface area 
of the human sclera accounts for 95% of the total surface 
area of the globe and provides a significantly larger avenue 
for drug diffusion to the inside of the eye than the 1-
cm2 surface area of the cornea. Also, regional differences in 
scleral thickness could be used to further optimize 
transscleral drug diffusion if sustained-release delivery 
devices or systems could be placed in regions where scleral 
permeability was greatest. The sclera, for example, is 1.0 mm 
thick near the optic nerve and an average of 0.53 mm thick 
at the corneoscleral limbus and thins to an average of 0.39 
mm at the equator, where it can be as thin as 0.1 mm in a 
significant number of eyes. Further, an increasing body of 
evidence suggests that the sclera is quite permeable to a 
wide range of solutes and holds significant potential for 
posterior segment drug delivery 29. 
Drug delivery across the sclera or cornea is governed in part 
by transient diffusion across the tissue that typically occurs 
over a time course of minutes unless some type of controlled 
release formulation or device is used. Experimental 
measurements of scleral permeability are, however, based 
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on determinations of steady state flux. It is important to note 
that in the absence of a sustained-release system, drug–
sclera contact times would be expected to be too brief to 
permit the attainment of steady state flux. Thus, in vitro flux 
measurements can be expected to over predict transscleral 
drug delivery. The utilization of some type of sustained-
release delivery system would appear to be necessary for 
successful utilization of transscleral drug delivery. The ideal 
sustained-release system would provide controlled, long-
term drug release, specific scleral site delivery and prolong 
drug-sclera contact time. This would permit improved drug 
flux through thinner areas of the tissue, potentially permit 
treatment to specific posterior segment regions, and 
minimize systemic drug absorption by the conjunctival 
vasculature. A wide variety of sustained-release drug 
delivery systems exist, including various gel formulations, 
erodible polymers, microspheres, liposomes, and various 
types of inserts, including miniosmotic pumps and 
combinations of these technologies. Two currently available 
technologies show exciting potential for transscleral 
application. In situ forming polymeric gels are viscous 
liquids that on exposure to physiological conditions will shift 
to a gel phase. Pluronic F-127 is a polyol compound that 
exhibits the phenomenon of reverse thermal gelation, 
remaining in the liquid state at refrigerator temperatures 
and gelling on warming to ambient or physiological 
temperatures. Bioadhesive compounds such as fibrin glue 
also hold great promise. Both Pluronic F-127 and fibrin glue 
have been used widely in medical and pharmaceutical 
systems. 15 16 These compounds have excellent tissue 
compatibility. Drugs can be incorporated into them, and the 
formulation can be applied to a scleral site, where it will 
quickly gel or solidify. Preliminary in vitro perfusion studies 
with F-127 and fibrin glue have demonstrated that they can 
provide slow, uniform sustained release of dexamethasone 
across human sclera 30. 
Experimental evidence currently shows that transscleral 
delivery of drugs can be accomplished and suggests great 
promise that this approach will provide new therapeutic 
approaches for treating visually devastating diseases of the 
posterior segment of the eye. Future studies will further 
define the feasibility of this approach 31. 
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